Hinge Health (NYSE:HNGE) Earns “Market Outperform” Rating from Citizens Jmp

Hinge Health (NYSE:HNGE)‘s stock had its “market outperform” rating reaffirmed by analysts at Citizens Jmp in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $65.00 price target on the stock. Citizens Jmp’s target price points to a potential upside of 64.39% from the stock’s current price.

A number of other research analysts also recently commented on the company. Wells Fargo & Company started coverage on Hinge Health in a report on Thursday, January 8th. They set an “overweight” rating and a $68.00 target price on the stock. Wall Street Zen lowered Hinge Health from a “buy” rating to a “hold” rating in a research report on Sunday, December 28th. Piper Sandler decreased their price objective on shares of Hinge Health from $71.00 to $60.00 and set an “overweight” rating for the company in a report on Friday, January 9th. Freedom Capital raised shares of Hinge Health to a “strong-buy” rating in a report on Thursday, January 22nd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $59.00 price target on shares of Hinge Health in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $57.71.

Hinge Health Stock Performance

Shares of HNGE stock opened at $39.54 on Wednesday. The stock has a market capitalization of $3.11 billion and a price-to-earnings ratio of -3.01. Hinge Health has a one year low of $30.08 and a one year high of $62.18. The company’s 50-day simple moving average is $43.76 and its 200-day simple moving average is $48.80.

Hinge Health announced that its board has initiated a share repurchase plan on Wednesday, November 12th that authorizes the company to repurchase $250.00 million in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 7.2% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board believes its stock is undervalued.

Insider Activity at Hinge Health

In other Hinge Health news, major shareholder Insight Holdings Group, Llc sold 1,654,440 shares of the business’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $47.76, for a total transaction of $79,016,054.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO James Budge sold 44,589 shares of the firm’s stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $47.47, for a total transaction of $2,116,639.83. Following the completion of the sale, the chief financial officer owned 479,878 shares in the company, valued at $22,779,808.66. The trade was a 8.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 2,805,105 shares of company stock valued at $128,216,614.

Hedge Funds Weigh In On Hinge Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HNGE. Lisanti Capital Growth LLC bought a new position in Hinge Health during the 2nd quarter valued at $3,089,000. JPMorgan Chase & Co. acquired a new stake in shares of Hinge Health in the second quarter valued at $43,840,000. Seven Grand Managers LLC bought a new position in Hinge Health during the second quarter valued at about $12,938,000. Strategic Blueprint LLC acquired a new position in Hinge Health during the second quarter worth about $346,000. Finally, Foresite Capital Management VI LLC bought a new stake in Hinge Health in the second quarter worth about $6,986,000.

More Hinge Health News

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Q4 beat — Hinge reported a Q4 revenue surge and earnings that materially exceeded estimates, driving investor optimism about near-term growth. Investing.com: Q4 earnings
• Positive Sentiment: 2026 guidance & AI investments — Management outlined a 2026 revenue target (~$732M) and a ~25% revenue growth target, citing expansion of AI-driven care that supports the stronger outlook. FierceHealthcare: 2026 revenue projection
• Positive Sentiment: Analyst support — Citizens JMP reaffirmed a “market outperform” rating and set a $65 price target, signaling substantial upside vs. current levels and backing the post-earnings enthusiasm. Benzinga: Citizens JMP
• Positive Sentiment: More buy-side reinforcement — Needham reiterated a “buy” rating with a $59 target, adding to constructive analyst commentary. TickerReport: Needham
• Neutral Sentiment: Investor materials available — The company published its Q4 earnings presentation and call transcript for detailed checks on margin trends, unit economics and AI investment cadence. Useful for investors wanting to validate guidance assumptions. Seeking Alpha: Earnings presentation
• Neutral Sentiment: Price action / volume — The stock posted a sizable intraday rally with volume well above average, reflecting short-covering and fresh buyer interest; this can amplify volatility in either direction. MSN: Intraday move
• Negative Sentiment: Mixed analyst actions — Barclays lowered its price target from $60 to $52 (still “overweight”), which trims some upside vs. the more bullish targets and highlights lingering analyst caution about sustained margins or execution risk. Benzinga: Barclays
• Negative Sentiment: Profitability risk — Despite the revenue beat, Hinge remains unprofitable (negative P/E), so investors should watch whether revenue growth translates into sustainable margins and cash flow over the next several quarters.

Hinge Health Company Profile

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.